ARTV
Artiva Biotherapeutics Inc. (ARTV)
Market Closed
12 Dec, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
3. 30
+0.16
+5.1%
$
85.17M Market Cap
- P/E Ratio
0% Div Yield
79,926 Volume
- Eps
$ 3.14
Previous Close Day Range
3.1 3.3
Year Range
1.47 11.55
Want to track ARTV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.
Fool | 1 year ago
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
In July, Artiva Biotherapeutics, Inc. ARTV priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.
Benzinga | 1 year ago
Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares
24/7 Wall St. Insights In the past week or so, initial public offerings at a biotech and an investment management firm attracted huge insider buying.
247wallst | 1 year ago
2025 © Marketlog. All Rights Reserved.
